Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 + PD-1 Inhibitor for Adjuvant Therapy in Liver Cancer
NCT07495215Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iNeo-Vac-R01 in hepatocellular carcinoma (HCC). Started Sep 2025; status: recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07495215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495215.